Medtronics Inc. names Martin Rothman vice president of medical affairs for its coronary and peripheral vascular business.
Medtronic Inc. (NYSE:MDT) tapped veteran British interventional cardiologist Martin Rothman to lead a portion of its vascular business.
The Minneapolis medical device monolith said Rothman will be vice president of medical affairs for its Santa Rosa, Calif.-based coronary and peripheral vascular business, effective Jan. 4. He spent the last 37 years in clinical practice at the London Chest Hospital, where he directed cardiac research and development for the past 10 years.
Philips bids on ultrasound-guided gene therapy; MED-EL's Vibrant Soundbridge middle ear implant gets EU OK; nanoparticles traverse blood-brain barrier to help improve MRI visualization; microchip system can perform hundreds of parallel chemical reactions; and the FDA OKs Peak Surgical's PlasmaBlade for tonsil and adenoid tissue removal.
Philips bids on ultrasound-guided gene therapy: Delivering DNA sequences to cells for gene therapy is already being investigated, with the current approaches relying on viruses and smart nanoparticles as vectors for gene transfer. But Philips and GlyGenix Therapeutics, out of Woodbridge, Conn., plan on taking another approach, hoping that the large molecules can be pushed to their destination using ultrasound. Specifically, the pre-clinical trials will study the technology, known as ultrasound-mediated plasmid DNA (pDNA) delivery, on Glycogen Storage Disease Type 1a (GSD-1a) that exhibits a defective G6Pase gene.
Static and Dynamic testing systems for materials, components, and devices. Systems range from 50 grams to 600kN of force capacity in tension, compression, torsion, and more.
Provides grips, fixtures, heating and cooling systems, and fluid baths.